Summary & Overview
HCPCS J1576: Immune Globulin (Panzyga) IV, 500 mg
HCPCS Level II code J1576 represents administration of immune globulin (Panzyga), intravenous, non-lyophilized (liquid), per 500 mg. This code is used to bill for doses of a plasma-derived immunoglobulin product delivered intravenously for immune replacement or modulation. Nationally, accurate coding for intravenous immunoglobulin (IVIG) products is important for standardized reimbursement, clinical documentation, and supply-chain management given the high cost and frequent use in immunodeficiency, autoimmune, and neurologic conditions.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for IVIG administration, descriptions of typical sites of service (hospital outpatient infusion centers, physician office infusion suites, ambulatory infusion centers), and what to expect in billing practice when using J1576 for Panzyga dosing. The publication outlines common billing considerations, benchmarking topics, and recent policy themes relevant to high-cost biologic infusions. Data not available in the input for specific reimbursement rates, associated taxonomies, ICD-10 diagnoses, and related codes are noted as unavailable in the input.
Billing Code Overview
HCPCS Level II code J1576 describes an intravenous injection of immune globulin (Panzyga), non-lyophilized (liquid), measured per 500 mg. The service represents administration of a plasma-derived immune globulin formulation used for immune modulation or replacement therapies.
Service type: Intravenous infusion/therapeutic infusion
Typical site of service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with primary immunodeficiency or a patient with an autoimmune or neurologic condition requiring intravenous immune globulin (IVIG) therapy who presents to an outpatient infusion center or hospital outpatient department for medication administration. The product administered is J1576 (immune globulin, Panzyga, intravenous, liquid, 500 mg unit). Clinical workflow: patient arrives for scheduled infusion following prior authorization and documented diagnosis; nursing performs baseline vitals and allergy review; an IV is established (peripheral or central access) and the IVIG is prepared and checked by pharmacy for dose calculation based on patient weight and concentration; infusion is initiated at a slow rate with vital sign monitoring and escalation of rate per protocol if tolerated; any infusion reactions are managed per institutional guidelines; infusion documentation includes lot numbers, units administered, start/stop times, infusion rate changes, and concomitant medications. Typical sites of service include outpatient infusion centers, hospital outpatient departments, and inpatient wards for acute or complex cases. Common accompanying processes include pre-infusion laboratory evaluation (e.g., CBC, CMP), management of infusion-related adverse effects, and coordination of payer authorization and billing using appropriate modifiers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |